TY - JOUR AU - Shweiki, D. AU - Itin, A. AU - Soffer, D. AU - Keshet, E. PY - 1992 DA - 1992// TI - Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis JO - Nature VL - 359 UR - https://doi.org/10.1038/359843a0 DO - 10.1038/359843a0 ID - Shweiki1992 ER - TY - JOUR AU - Ferrara, N. PY - 2016 DA - 2016// TI - Vegf and intraocular neovascularization: from discovery to therapy JO - Transl Vis Sci Technol VL - 5 UR - https://doi.org/10.1167/tvst.5.2.10 DO - 10.1167/tvst.5.2.10 ID - Ferrara2016 ER - TY - JOUR AU - Aiello, L. P. AU - Avery, R. L. AU - Arrigg, P. G. PY - 1994 DA - 1994// TI - Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders JO - N Engl J Med VL - 331 UR - https://doi.org/10.1056/NEJM199412013312203 DO - 10.1056/NEJM199412013312203 ID - Aiello1994 ER - TY - JOUR AU - Funk, M. AU - Karl, D. AU - Georgopoulos, M. PY - 2009 DA - 2009// TI - Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab JO - Ophthalmology VL - 116 UR - https://doi.org/10.1016/j.ophtha.2009.05.039 DO - 10.1016/j.ophtha.2009.05.039 ID - Funk2009 ER - TY - JOUR AU - Funatsu, H. AU - Yamashita, H. AU - Sakata, K. PY - 2005 DA - 2005// TI - Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema JO - Ophthalmology VL - 112 UR - https://doi.org/10.1016/j.ophtha.2004.11.045 DO - 10.1016/j.ophtha.2004.11.045 ID - Funatsu2005 ER - TY - STD TI - Genentech. Lucentis Prescribing Information. 2017. ID - ref6 ER - TY - STD TI - Aflibercept Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125387s054lbl.pdf. Accessed 15 April 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125387s054lbl.pdf ID - ref7 ER - TY - STD TI - Novartis. Beovu Prescribing Information. 2019. ID - ref8 ER - TY - JOUR AU - Low, A. AU - Faridi, A. AU - Bhavsar, K. V. PY - 2019 DA - 2019// TI - Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis JO - Br J Ophthalmol VL - 103 UR - https://doi.org/10.1136/bjophthalmol-2018-312691 DO - 10.1136/bjophthalmol-2018-312691 ID - Low2019 ER - TY - JOUR AU - Wykoff, C. C. AU - Ou, W. C. AU - Brown, D. M. PY - 2017 DA - 2017// TI - Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the trex-amd study JO - Ophthalmol Retina VL - 1 UR - https://doi.org/10.1016/j.oret.2016.12.004 DO - 10.1016/j.oret.2016.12.004 ID - Wykoff2017 ER - TY - JOUR AU - Silva, R. AU - Berta, A. AU - Larsen, M. PY - 2018 DA - 2018// TI - Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the trend study JO - Ophthalmology VL - 125 UR - https://doi.org/10.1016/j.ophtha.2017.07.014 DO - 10.1016/j.ophtha.2017.07.014 ID - Silva2018 ER - TY - JOUR AU - Kertes, P. J. AU - Galic, I. J. AU - Greve, M. PY - 2019 DA - 2019// TI - Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian treat-and-extend analysis trial with ranibizumab study JO - Ophthalmology VL - 126 UR - https://doi.org/10.1016/j.ophtha.2019.01.013 DO - 10.1016/j.ophtha.2019.01.013 ID - Kertes2019 ER - TY - JOUR AU - Berg, K. AU - Hadzalic, E. AU - Gjertsen, I. PY - 2016 DA - 2016// TI - Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results JO - Ophthalmology VL - 123 UR - https://doi.org/10.1016/j.ophtha.2015.09.018 DO - 10.1016/j.ophtha.2015.09.018 ID - Berg2016 ER - TY - JOUR AU - DeCroos, F. C. AU - Reed, D. AU - Adam, M. K. PY - 2017 DA - 2017// TI - Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial JO - Am J Ophthalmol VL - 180 UR - https://doi.org/10.1016/j.ajo.2017.06.002 DO - 10.1016/j.ajo.2017.06.002 ID - DeCroos2017 ER - TY - JOUR AU - Ohji, M. AU - Takahashi, K. AU - Okada, A. A. PY - 2020 DA - 2020// TI - Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from altair: a randomized controlled trial JO - Adv Ther VL - 37 UR - https://doi.org/10.1007/s12325-020-01236-x DO - 10.1007/s12325-020-01236-x ID - Ohji2020 ER - TY - STD TI - Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D. Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2016;123:2545–53. ID - ref16 ER - TY - JOUR AU - Holz, F. G. AU - Bandello, F. AU - Gillies, M. PY - 2013 DA - 2013// TI - Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four european neovascular amd registries within the luminous programme JO - Br J Ophthalmol VL - 97 UR - https://doi.org/10.1136/bjophthalmol-2013-303232 DO - 10.1136/bjophthalmol-2013-303232 ID - Holz2013 ER - TY - JOUR AU - Holz, F. G. AU - Tadayoni, R. AU - Beatty, S. PY - 2015 DA - 2015// TI - Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration JO - Br J Ophthalmol VL - 99 UR - https://doi.org/10.1136/bjophthalmol-2014-305327 DO - 10.1136/bjophthalmol-2014-305327 ID - Holz2015 ER - TY - STD TI - Writing Committee for the, U. K. Age-Related Macular Degeneration E. M. R. Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121:1092–101. ID - ref19 ER - TY - JOUR AU - Kim, L. N. AU - Mehta, H. AU - Barthelmes, D. AU - Nguyen, V. AU - Gillies, M. C. PY - 2016 DA - 2016// TI - Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration JO - Retina VL - 36 UR - https://doi.org/10.1097/IAE.0000000000001142 DO - 10.1097/IAE.0000000000001142 ID - Kim2016 ER - TY - JOUR AU - Wells, J. A. AU - Glassman, A. R. AU - Ayala, A. R. PY - 2016 DA - 2016// TI - Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial JO - Ophthalmology VL - 123 UR - https://doi.org/10.1016/j.ophtha.2016.02.022 DO - 10.1016/j.ophtha.2016.02.022 ID - Wells2016 ER - TY - JOUR AU - Broadhead, G. K. AU - Hong, T. AU - Chang, A. A. PY - 2014 DA - 2014// TI - Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration JO - Acta Ophthalmol VL - 92 UR - https://doi.org/10.1111/aos.12463 DO - 10.1111/aos.12463 ID - Broadhead2014 ER - TY - JOUR AU - Hussain, R. M. AU - Ciulla, T. A. PY - 2016 DA - 2016// TI - Treatment strategies for refractory diabetic macular edema: switching anti-vegf treatments, adopting corticosteroid-based treatments, and combination therapy JO - Expert Opin Biol Ther VL - 16 UR - https://doi.org/10.1517/14712598.2016.1131265 DO - 10.1517/14712598.2016.1131265 ID - Hussain2016 ER - TY - JOUR AU - Abokyi, S. AU - To, C. H. AU - Lam, T. T. AU - Tse, D. Y. PY - 2020 DA - 2020// TI - Central role of oxidative stress in age-related macular degeneration: evidence from a review of the molecular mechanisms and animal models JO - Oxid Med Cell Longev VL - 2020 ID - Abokyi2020 ER - TY - JOUR AU - Wu, J. AU - Sun, X. PY - 2019 DA - 2019// TI - Complement system and age-related macular degeneration: drugs and challenges JO - Drug Design Dev Therapy VL - 13 UR - https://doi.org/10.2147/DDDT.S206355 DO - 10.2147/DDDT.S206355 ID - Wu2019 ER - TY - JOUR AU - Choudhary, M. AU - Malek, G. PY - 2019 DA - 2019// TI - A review of pathogenic drivers of age-related macular degeneration, beyond complement, with a focus on potential endpoints for testing therapeutic interventions in preclinical studies JO - Adv Exp Med Biol VL - 1185 UR - https://doi.org/10.1007/978-3-030-27378-1_2 DO - 10.1007/978-3-030-27378-1_2 ID - Choudhary2019 ER - TY - JOUR AU - Hussain, R. M. AU - Neiweem, A. E. AU - Kansara, V. AU - Harris, A. AU - Ciulla, T. A. PY - 2019 DA - 2019// TI - Tie-2/angiopoietin pathway modulation as a therapeutic strategy for retinal disease JO - Expert Opin Investig Drugs VL - 28 UR - https://doi.org/10.1080/13543784.2019.1667333 DO - 10.1080/13543784.2019.1667333 ID - Hussain2019 ER - TY - JOUR AU - Miller, K. AU - Fortun, J. A. PY - 2018 DA - 2018// TI - Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies JO - Asia Pac J Ophthalmol (Phila) VL - 7 ID - Miller2018 ER - TY - JOUR AU - Campochiaro, P. A. PY - 2015 DA - 2015// TI - Molecular pathogenesis of retinal and choroidal vascular diseases JO - Prog Retin Eye Res VL - 49 UR - https://doi.org/10.1016/j.preteyeres.2015.06.002 DO - 10.1016/j.preteyeres.2015.06.002 ID - Campochiaro2015 ER - TY - JOUR AU - Partanen, J. AU - Armstrong, E. AU - Makela, T. P. PY - 1992 DA - 1992// TI - A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains JO - Mol Cell Biol VL - 12 UR - https://doi.org/10.1128/MCB.12.4.1698 DO - 10.1128/MCB.12.4.1698 ID - Partanen1992 ER - TY - JOUR AU - Sato, T. N. AU - Qin, Y. AU - Kozak, C. A. AU - Audus, K. L. PY - 1993 DA - 1993// TI - Tie-1 and Tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system JO - Proc Natl Acad Sci USA VL - 90 UR - https://doi.org/10.1073/pnas.90.20.9355 DO - 10.1073/pnas.90.20.9355 ID - Sato1993 ER - TY - JOUR AU - Maisonpierre, P. C. AU - Suri, C. AU - Jones, P. F. PY - 1997 DA - 1997// TI - Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis JO - Science VL - 277 UR - https://doi.org/10.1126/science.277.5322.55 DO - 10.1126/science.277.5322.55 ID - Maisonpierre1997 ER - TY - JOUR AU - Davis, S. AU - Aldrich, T. H. AU - Jones, P. F. PY - 1996 DA - 1996// TI - Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning JO - Cell VL - 87 UR - https://doi.org/10.1016/S0092-8674(00)81812-7 DO - 10.1016/S0092-8674(00)81812-7 ID - Davis1996 ER - TY - JOUR AU - Thurston, G. AU - Daly, C. PY - 2012 DA - 2012// TI - The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway JO - Cold Spring Harb Perspect Med VL - 2 UR - https://doi.org/10.1101/cshperspect.a006650 DO - 10.1101/cshperspect.a006650 ID - Thurston2012 ER - TY - JOUR AU - Schnurch, H. AU - Risau, W. PY - 1993 DA - 1993// TI - Expression of Tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage JO - Development VL - 119 ID - Schnurch1993 ER - TY - JOUR AU - Saharinen, P. AU - Kerkela, K. AU - Ekman, N. PY - 2005 DA - 2005// TI - Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2 JO - J Cell Biol VL - 169 UR - https://doi.org/10.1083/jcb.200411105 DO - 10.1083/jcb.200411105 ID - Saharinen2005 ER - TY - JOUR AU - Fiedler, U. AU - Krissl, T. AU - Koidl, S. PY - 2003 DA - 2003// TI - Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats JO - J Biol Chem VL - 278 UR - https://doi.org/10.1074/jbc.M208550200 DO - 10.1074/jbc.M208550200 ID - Fiedler2003 ER - TY - JOUR AU - Stratmann, A. AU - Risau, W. AU - Plate, K. H. PY - 1998 DA - 1998// TI - Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis JO - Am J Pathol VL - 153 UR - https://doi.org/10.1016/S0002-9440(10)65733-1 DO - 10.1016/S0002-9440(10)65733-1 ID - Stratmann1998 ER - TY - JOUR AU - Reiss, Y. AU - Droste, J. AU - Heil, M. PY - 2007 DA - 2007// TI - Angiopoietin-2 impairs revascularization after limb ischemia JO - Circ Res VL - 101 UR - https://doi.org/10.1161/CIRCRESAHA.106.143594 DO - 10.1161/CIRCRESAHA.106.143594 ID - Reiss2007 ER - TY - JOUR AU - Scharpfenecker, M. AU - Fiedler, U. AU - Reiss, Y. AU - Augustin, H. G. PY - 2005 DA - 2005// TI - The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism JO - J Cell Sci VL - 118 UR - https://doi.org/10.1242/jcs.01653 DO - 10.1242/jcs.01653 ID - Scharpfenecker2005 ER - TY - JOUR AU - Daly, C. AU - Pasnikowski, E. AU - Burova, E. PY - 2006 DA - 2006// TI - Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells JO - Proc Natl Acad Sci USA VL - 103 UR - https://doi.org/10.1073/pnas.0607538103 DO - 10.1073/pnas.0607538103 ID - Daly2006 ER - TY - JOUR AU - Tabruyn, S. P. AU - Colton, K. AU - Morisada, T. PY - 2010 DA - 2010// TI - Angiopoietin-2-driven vascular remodeling in airway inflammation JO - Am J Pathol VL - 177 UR - https://doi.org/10.2353/ajpath.2010.100059 DO - 10.2353/ajpath.2010.100059 ID - Tabruyn2010 ER - TY - JOUR AU - Kim, K. T. AU - Choi, H. H. AU - Steinmetz, M. O. PY - 2005 DA - 2005// TI - Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2 JO - J Biol Chem VL - 280 UR - https://doi.org/10.1074/jbc.M500292200 DO - 10.1074/jbc.M500292200 ID - Kim2005 ER - TY - JOUR AU - Moore, J. O. AU - Lemmon, M. A. AU - Ferguson, K. M. PY - 2017 DA - 2017// TI - Dimerization of Tie2 mediated by its membrane-proximal fniii domains JO - Proc Natl Acad Sci USA VL - 114 UR - https://doi.org/10.1073/pnas.1617800114 DO - 10.1073/pnas.1617800114 ID - Moore2017 ER - TY - JOUR AU - Davis, S. AU - Papadopoulos, N. AU - Aldrich, T. H. PY - 2003 DA - 2003// TI - Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering JO - Nat Struct Biol VL - 10 UR - https://doi.org/10.1038/nsb880 DO - 10.1038/nsb880 ID - Davis2003 ER - TY - JOUR AU - Li, Z. AU - Huang, H. AU - Boland, P. PY - 2009 DA - 2009// TI - Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis JO - Proc Natl Acad Sci USA VL - 106 UR - https://doi.org/10.1073/pnas.0911189106 DO - 10.1073/pnas.0911189106 ID - Li2009 ER - TY - JOUR AU - Winderlich, M. AU - Keller, L. AU - Cagna, G. PY - 2009 DA - 2009// TI - Ve-Ptp controls blood vessel development by balancing Tie-2 activity JO - J Cell Biol VL - 185 UR - https://doi.org/10.1083/jcb.200811159 DO - 10.1083/jcb.200811159 ID - Winderlich2009 ER - TY - JOUR AU - Frye, M. AU - Dierkes, M. AU - Kuppers, V. PY - 2015 DA - 2015// TI - Interfering with Ve-Ptp stabilizes endothelial junctions in vivo via Tie-2 in the absence of ve-cadherin JO - J Exp Med VL - 212 UR - https://doi.org/10.1084/jem.20150718 DO - 10.1084/jem.20150718 ID - Frye2015 ER - TY - JOUR AU - Papapetropoulos, A. AU - Fulton, D. AU - Mahboubi, K. PY - 2000 DA - 2000// TI - Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway JO - J Biol Chem VL - 275 UR - https://doi.org/10.1074/jbc.275.13.9102 DO - 10.1074/jbc.275.13.9102 ID - Papapetropoulos2000 ER - TY - JOUR AU - Kontos, C. D. AU - Cha, E. H. AU - York, J. D. AU - Peters, K. G. PY - 2002 DA - 2002// TI - The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and akt to inhibit apoptosis JO - Mol Cell Biol VL - 22 UR - https://doi.org/10.1128/MCB.22.6.1704-1713.2002 DO - 10.1128/MCB.22.6.1704-1713.2002 ID - Kontos2002 ER - TY - JOUR AU - Daly, C. AU - Wong, V. AU - Burova, E. PY - 2004 DA - 2004// TI - Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor Fkhr (Foxo1) JO - Genes Dev VL - 18 UR - https://doi.org/10.1101/gad.1189704 DO - 10.1101/gad.1189704 ID - Daly2004 ER - TY - JOUR AU - Kanda, S. AU - Miyata, Y. AU - Mochizuki, Y. AU - Matsuyama, T. AU - Kanetake, H. PY - 2005 DA - 2005// TI - Angiopoietin 1 is mitogenic for cultured endothelial cells JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-05-0522 DO - 10.1158/0008-5472.CAN-05-0522 ID - Kanda2005 ER - TY - JOUR AU - Koblizek, T. I. AU - Weiss, C. AU - Yancopoulos, G. D. AU - Deutsch, U. AU - Risau, W. PY - 1998 DA - 1998// TI - Angiopoietin-1 induces sprouting angiogenesis in vitro JO - Curr Biol VL - 8 UR - https://doi.org/10.1016/S0960-9822(98)70205-2 DO - 10.1016/S0960-9822(98)70205-2 ID - Koblizek1998 ER - TY - JOUR AU - Augustin, H. G. AU - Koh, G. Y. AU - Thurston, G. AU - Alitalo, K. PY - 2009 DA - 2009// TI - Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system JO - Nat Rev Mol Cell Biol VL - 10 UR - https://doi.org/10.1038/nrm2639 DO - 10.1038/nrm2639 ID - Augustin2009 ER - TY - JOUR AU - Hughes, D. P. AU - Marron, M. B. AU - Brindle, N. P. PY - 2003 DA - 2003// TI - the antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappab inhibitor abin-2 JO - Circ Res VL - 92 UR - https://doi.org/10.1161/01.RES.0000063422.38690.DC DO - 10.1161/01.RES.0000063422.38690.DC ID - Hughes2003 ER - TY - STD TI - Ziegler T, Horstkotte J, Schwab C, et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest. 2013. ID - ref56 ER - TY - JOUR AU - Menden, H. AU - Welak, S. AU - Cossette, S. AU - Ramchandran, R. AU - Sampath, V. PY - 2015 DA - 2015// TI - Lipopolysaccharide (Lps)-mediated angiopoietin-2-dependent autocrine angiogenesis is regulated by nadph oxidase 2 (Nox2) in human pulmonary microvascular endothelial cells JO - J Biol Chem VL - 290 UR - https://doi.org/10.1074/jbc.M114.600692 DO - 10.1074/jbc.M114.600692 ID - Menden2015 ER - TY - JOUR AU - Sato, T. N. AU - Tozawa, Y. AU - Deutsch, U. PY - 1995 DA - 1995// TI - Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation JO - Nature VL - 376 UR - https://doi.org/10.1038/376070a0 DO - 10.1038/376070a0 ID - Sato1995 ER - TY - JOUR AU - Dumont, D. J. AU - Gradwohl, G. AU - Fong, G. H. PY - 1994 DA - 1994// TI - Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo JO - Genes Dev VL - 8 UR - https://doi.org/10.1101/gad.8.16.1897 DO - 10.1101/gad.8.16.1897 ID - Dumont1994 ER - TY - JOUR AU - Suri, C. AU - Jones, P. F. AU - Patan, S. PY - 1996 DA - 1996// TI - Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis JO - Cell VL - 87 UR - https://doi.org/10.1016/S0092-8674(00)81813-9 DO - 10.1016/S0092-8674(00)81813-9 ID - Suri1996 ER - TY - JOUR AU - Suri, C. AU - McClain, J. AU - Thurston, G. PY - 1998 DA - 1998// TI - Increased vascularization in mice overexpressing angiopoietin-1 JO - Science VL - 282 UR - https://doi.org/10.1126/science.282.5388.468 DO - 10.1126/science.282.5388.468 ID - Suri1998 ER - TY - JOUR AU - Thurston, G. AU - Rudge, J. S. AU - Ioffe, E. PY - 2000 DA - 2000// TI - Angiopoietin-1 protects the adult vasculature against plasma leakage JO - Nat Med VL - 6 UR - https://doi.org/10.1038/74725 DO - 10.1038/74725 ID - Thurston2000 ER - TY - JOUR AU - Gale, N. W. AU - Thurston, G. AU - Hackett, S. F. PY - 2002 DA - 2002// TI - Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1 JO - Dev Cell VL - 3 UR - https://doi.org/10.1016/S1534-5807(02)00217-4 DO - 10.1016/S1534-5807(02)00217-4 ID - Gale2002 ER - TY - JOUR AU - Ma, L. AU - Brelen, M. E. AU - Tsujikawa, M. PY - 2017 DA - 2017// TI - Identification of Angpt2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations JO - Invest Ophthalmol Vis Sci VL - 58 UR - https://doi.org/10.1167/iovs.16-20575 DO - 10.1167/iovs.16-20575 ID - Ma2017 ER - TY - JOUR AU - Ng, D. S. AU - Yip, Y. W. AU - Bakthavatsalam, M. PY - 2017 DA - 2017// TI - Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/srep45081 DO - 10.1038/srep45081 ID - Ng2017 ER - TY - JOUR AU - Hera, R. AU - Keramidas, M. AU - Peoc’h, M. AU - Mouillon, M. AU - Romanet, J. P. AU - Feige, J. J. PY - 2005 DA - 2005// TI - Expression of Vegf and angiopoietins in subfoveal membranes from patients with age-related macular degeneration JO - Am J Ophthalmol VL - 139 UR - https://doi.org/10.1016/j.ajo.2004.11.064 DO - 10.1016/j.ajo.2004.11.064 ID - Hera2005 ER - TY - JOUR AU - Otani, A. AU - Takagi, H. AU - Oh, H. AU - Koyama, S. AU - Matsumura, M. AU - Honda, Y. PY - 1999 DA - 1999// TI - Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes JO - Invest Ophthalmol Vis Sci VL - 40 ID - Otani1999 ER - TY - JOUR AU - Huber, M. AU - Wachtlin, J. PY - 2012 DA - 2012// TI - Vitreous levels of proteins implicated in angiogenesis are modulated in patients with retinal or choroidal neovascularization JO - Ophthalmologica VL - 228 UR - https://doi.org/10.1159/000339952 DO - 10.1159/000339952 ID - Huber2012 ER - TY - JOUR AU - Tuuminen, R. AU - Loukovaara, S. PY - 2014 DA - 2014// TI - Increased intravitreal angiopoietin-2 levels in patients with retinal vein occlusion JO - Acta Ophthalmol VL - 92 UR - https://doi.org/10.1111/aos.12223 DO - 10.1111/aos.12223 ID - Tuuminen2014 ER - TY - JOUR AU - Lee, J. AU - Park, D. Y. AU - Park, D. Y. PY - 2014 DA - 2014// TI - Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage JO - Invest Ophthalmol Vis Sci VL - 55 UR - https://doi.org/10.1167/iovs.14-13897 DO - 10.1167/iovs.14-13897 ID - Lee2014 ER - TY - JOUR AU - Peters, S. AU - Cree, I. A. AU - Alexander, R. PY - 2007 DA - 2007// TI - Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability JO - Cytokine VL - 40 UR - https://doi.org/10.1016/j.cyto.2007.09.001 DO - 10.1016/j.cyto.2007.09.001 ID - Peters2007 ER - TY - JOUR AU - Oh, H. AU - Takagi, H. AU - Suzuma, K. AU - Otani, A. AU - Matsumura, M. AU - Honda, Y. PY - 1999 DA - 1999// TI - Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells JO - J Biol Chem VL - 274 UR - https://doi.org/10.1074/jbc.274.22.15732 DO - 10.1074/jbc.274.22.15732 ID - Oh1999 ER - TY - JOUR AU - Ohashi, H. AU - Takagi, H. AU - Koyama, S. PY - 2004 DA - 2004// TI - Alterations in expression of angiopoietins and the Tie-2 receptor in the retina of streptozotocin induced diabetic rats JO - Mol Vis VL - 10 ID - Ohashi2004 ER - TY - JOUR AU - Park, S. W. AU - Yun, J. H. AU - Kim, J. H. AU - Kim, K. W. AU - Cho, C. H. AU - Kim, J. H. PY - 2014 DA - 2014// TI - Angiopoietin 2 induces pericyte apoptosis via Alpha3beta1 integrin signaling in diabetic retinopathy JO - Diabetes VL - 63 UR - https://doi.org/10.2337/db13-1942 DO - 10.2337/db13-1942 ID - Park2014 ER - TY - JOUR AU - Lee, S. G. AU - Lee, C. G. AU - Yun, I. H. AU - Hur, D. Y. AU - Yang, J. W. AU - Kim, H. W. PY - 2012 DA - 2012// TI - Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina JO - Clin Exp Ophthalmol VL - 40 UR - https://doi.org/10.1111/j.1442-9071.2011.02695.x DO - 10.1111/j.1442-9071.2011.02695.x ID - Lee2012 ER - TY - JOUR AU - Watanabe, D. AU - Suzuma, K. AU - Suzuma, I. PY - 2005 DA - 2005// TI - Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy JO - Am J Ophthalmol VL - 139 UR - https://doi.org/10.1016/j.ajo.2004.10.004 DO - 10.1016/j.ajo.2004.10.004 ID - Watanabe2005 ER - TY - JOUR AU - Loukovaara, S. AU - Robciuc, A. AU - Holopainen, J. M. PY - 2013 DA - 2013// TI - Ang-2 upregulation correlates with increased levels of Mmp-9, Vegf, Epo and Tgfbeta1 in diabetic eyes undergoing vitrectomy JO - Acta Ophthalmol VL - 91 UR - https://doi.org/10.1111/j.1755-3768.2012.02473.x DO - 10.1111/j.1755-3768.2012.02473.x ID - Loukovaara2013 ER - TY - JOUR AU - Khalaf, N. AU - Helmy, H. AU - Labib, H. AU - Fahmy, I. AU - Hamid, M. A. AU - Moemen, L. PY - 2017 DA - 2017// TI - Role of angiopoietins and Tie-2 in diabetic retinopathy JO - Elect Phys VL - 9 UR - https://doi.org/10.19082/5031 DO - 10.19082/5031 ID - Khalaf2017 ER - TY - JOUR AU - Liu, X. W. AU - Ma, T. AU - Liu, W. PY - 2018 DA - 2018// TI - Sustained increase in angiopoietin-2, heparin-binding protein, and procalcitonin is associated with severe sepsis JO - J Crit Care VL - 45 UR - https://doi.org/10.1016/j.jcrc.2018.01.010 DO - 10.1016/j.jcrc.2018.01.010 ID - Liu2018 ER - TY - JOUR AU - Lymperopoulou, K. AU - Velissaris, D. AU - Kotsaki, A. PY - 2015 DA - 2015// TI - Angiopoietin-2 associations with the underlying infection and sepsis severity JO - Cytokine VL - 73 UR - https://doi.org/10.1016/j.cyto.2015.01.022 DO - 10.1016/j.cyto.2015.01.022 ID - Lymperopoulou2015 ER - TY - JOUR AU - Tee, J. K. AU - Setyawati, M. I. AU - Peng, F. AU - Leong, D. T. AU - Ho, H. K. PY - 2019 DA - 2019// TI - Angiopoietin-1 accelerates restoration of endothelial cell barrier integrity from nanoparticle-induced leakiness JO - Nanotoxicology VL - 13 UR - https://doi.org/10.1080/17435390.2019.1571646 DO - 10.1080/17435390.2019.1571646 ID - Tee2019 ER - TY - STD TI - Mirando AC, Shen J, Silva RLE, et al. A collagen Iv-derived peptide disrupts alpha5beta1 integrin and potentiates Ang2/Tie2 signaling. JCI Insight 2019;4. ID - ref82 ER - TY - JOUR AU - Dekker, N. A. M. AU - Meurs, M. AU - Leeuwen, A. L. I. PY - 2018 DA - 2018// TI - Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats JO - Br J Anaesth VL - 121 UR - https://doi.org/10.1016/j.bja.2018.05.049 DO - 10.1016/j.bja.2018.05.049 ID - Dekker2018 ER - TY - JOUR AU - Gurnik, S. AU - Devraj, K. AU - Macas, J. PY - 2016 DA - 2016// TI - Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by Ve-Ptp-dependent restoration of Tie2 signaling JO - Acta Neuropathol VL - 131 UR - https://doi.org/10.1007/s00401-016-1551-3 DO - 10.1007/s00401-016-1551-3 ID - Gurnik2016 ER - TY - JOUR AU - Rubig, E. AU - Stypmann, J. AU - Slyke, P. PY - 2016 DA - 2016// TI - The synthetic Tie2 agonist peptide vasculotide protects renal vascular barrier function in experimental acute kidney injury JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep22111 DO - 10.1038/srep22111 ID - Rubig2016 ER - TY - JOUR AU - Wang, Y. AU - Wang, V. M. AU - Chan, C. C. PY - 2011 DA - 2011// TI - The role of anti-inflammatory agents in age-related macular degeneration (Amd) treatment JO - Eye (Lond) VL - 25 UR - https://doi.org/10.1038/eye.2010.196 DO - 10.1038/eye.2010.196 ID - Wang2011 ER - TY - JOUR AU - Doganay, S. AU - Evereklioglu, C. AU - Er, H. PY - 2002 DA - 2002// TI - Comparison of serum No, Tnf-Alpha, Il-1beta, Sil-2r, Il-6 and Il-8 levels with grades of retinopathy in patients with diabetes mellitus JO - Eye (Lond) VL - 16 UR - https://doi.org/10.1038/sj/eye/6700095 DO - 10.1038/sj/eye/6700095 ID - Doganay2002 ER - TY - JOUR AU - Deobhakta, A. AU - Chang, L. K. PY - 2013 DA - 2013// TI - Inflammation in retinal vein occlusion JO - Int J Inflam VL - 2013 UR - https://doi.org/10.1155/2013/438412 DO - 10.1155/2013/438412 ID - Deobhakta2013 ER - TY - JOUR AU - Scholz, A. AU - Plate, K. H. AU - Reiss, Y. PY - 2015 DA - 2015// TI - Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation JO - Ann N Y Acad Sci VL - 1347 UR - https://doi.org/10.1111/nyas.12726 DO - 10.1111/nyas.12726 ID - Scholz2015 ER - TY - JOUR AU - Gavard, J. AU - Patel, V. AU - Gutkind, J. S. PY - 2008 DA - 2008// TI - Angiopoietin-1 prevents vegf-induced endothelial permeability by sequestering src through Mdia JO - Dev Cell VL - 14 UR - https://doi.org/10.1016/j.devcel.2007.10.019 DO - 10.1016/j.devcel.2007.10.019 ID - Gavard2008 ER - TY - JOUR AU - Gavard, J. AU - Gutkind, J. S. PY - 2006 DA - 2006// TI - Vegf controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of Ve-cadherin JO - Nat Cell Biol VL - 8 UR - https://doi.org/10.1038/ncb1486 DO - 10.1038/ncb1486 ID - Gavard2006 ER - TY - STD TI - Silva RLE, Kanan Y, Mirando AC, et al. Tyrosine kinase blocking collagen iv-derived peptide suppresses ocular neovascularization and vascular leakage. Sci Transl Med. 2017;9. ID - ref92 ER - TY - STD TI - Mirando AC, Silva RLE, Chu Z, Campochiaro P, Popel AS, Pandey NB. Supression of ocular inflammation by a Tie2 activating peptide (in Press). ID - ref93 ER - TY - JOUR AU - Senger, D. R. AU - Davis, G. E. PY - 2011 DA - 2011// TI - Angiogenesis JO - Cold Spring Harbor Persp Biol VL - 3 ID - Senger2011 ER - TY - JOUR AU - O’Reilly, M. S. AU - Boehm, T. AU - Shing, Y. PY - 1997 DA - 1997// TI - Endostatin: an endogenous inhibitor of angiogenesis and tumor growth JO - Cell VL - 88 UR - https://doi.org/10.1016/S0092-8674(00)81848-6 DO - 10.1016/S0092-8674(00)81848-6 ID - O’Reilly1997 ER - TY - JOUR AU - Maeshima, Y. AU - Colorado, P. C. AU - Torre, A. PY - 2000 DA - 2000// TI - Distinct antitumor properties of a type Iv collagen domain derived from basement membrane JO - J Biol Chem VL - 275 UR - https://doi.org/10.1074/jbc.M001956200 DO - 10.1074/jbc.M001956200 ID - Maeshima2000 ER - TY - JOUR AU - Karagiannis, E. D. AU - Popel, A. S. PY - 2008 DA - 2008// TI - A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells JO - Proc Natl Acad Sci USA VL - 105 UR - https://doi.org/10.1073/pnas.0803241105 DO - 10.1073/pnas.0803241105 ID - Karagiannis2008 ER - TY - JOUR AU - Francis, S. E. AU - Goh, K. L. AU - Hodivala-Dilke, K. PY - 2002 DA - 2002// TI - Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies JO - Arterioscler Thromb Vasc Biol VL - 22 UR - https://doi.org/10.1161/01.ATV.0000016045.93313.F2 DO - 10.1161/01.ATV.0000016045.93313.F2 ID - Francis2002 ER - TY - JOUR AU - Hynes, R. O. PY - 2007 DA - 2007// TI - Cell-matrix adhesion in vascular development JO - J Thromb Haemost VL - 5 UR - https://doi.org/10.1111/j.1538-7836.2007.02569.x DO - 10.1111/j.1538-7836.2007.02569.x ID - Hynes2007 ER - TY - JOUR AU - Umeda, N. AU - Kachi, S. AU - Akiyama, H. PY - 2006 DA - 2006// TI - Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist JO - Mol Pharmacol VL - 69 UR - https://doi.org/10.1124/mol.105.020941 DO - 10.1124/mol.105.020941 ID - Umeda2006 ER - TY - JOUR AU - Soldi, R. AU - Mitola, S. AU - Strasly, M. AU - Defilippi, P. AU - Tarone, G. AU - Bussolino, F. PY - 1999 DA - 1999// TI - Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2 JO - EMBO J VL - 18 UR - https://doi.org/10.1093/emboj/18.4.882 DO - 10.1093/emboj/18.4.882 ID - Soldi1999 ER - TY - STD TI - Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265–88. ID - ref102 ER - TY - STD TI - Gahn GM, Khanani AM. New therapies of neovascular amd beyond anti-vegf injections. Vision (Basel). 2018;2. ID - ref103 ER - TY - STD TI - Helzner J. Faricimab shows potential for 16-week dosing: initial data presented from genentech’s stairway study. Retinal Phys. 2018. ID - ref104 ER - TY - STD TI - Khanani AM. Simulataneous Inhibition of Ang-2 and Vegf with faricimab in neovascular amd: stairway phase 2 results. American academy of ophthalmology retina subspecialty day. San Franciso, CA2019. ID - ref105 ER - TY - JOUR AU - Sahni, J. AU - Patel, S. S. AU - Dugel, P. U. PY - 2019 DA - 2019// TI - Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: boulevard phase 2 randomized trial JO - Ophthalmology VL - 126 UR - https://doi.org/10.1016/j.ophtha.2019.03.023 DO - 10.1016/j.ophtha.2019.03.023 ID - Sahni2019 ER - TY - STD TI - Clinicaltrials. Gov. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (Tenaya). https://clinicaltrials.gov/ct2/show/NCT03823287?term=faricimab&draw=2&rank=1.). Accessed 25 Nov 2019. UR - https://clinicaltrials.gov/ct2/show/NCT03823287%3fterm%3dfaricimab%26draw%3d2%26rank%3d1.) ID - ref107 ER - TY - STD TI - Clinicaltrials. Gov. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (Lucerne). https://clinicaltrials.gov/ct2/show/NCT03823300?term=faricimab&draw=2&rank=2.). Accessed 25 Nov 2019. UR - https://clinicaltrials.gov/ct2/show/NCT03823300%3fterm%3dfaricimab%26draw%3d2%26rank%3d2.) ID - ref108 ER - TY - STD TI - Clinicaltrials.Gov. A study to evaluate the efficacy and safety of faricimab (Ro6867461) in participants with diabetic macular edema (Rhine). (Accessed April 4, 2020, at a study to evaluate the efficacy and safety of Faricimab (RO6867461) in participants with diabetic macular edema (RHINE).). ID - ref109 ER - TY - STD TI - Clinicaltrials. Gov. A study to evaluate the efficacy and safety of faricimab (Ro6867461) in participants with diabetic macular edema (Yosemite). https://clinicaltrials.gov/ct2/show/NCT03622580?term=faricimab&draw=2&rank=3.). Accessed 4 April 2020. UR - https://clinicaltrials.gov/ct2/show/NCT03622580%3fterm%3dfaricimab%26draw%3d2%26rank%3d3.) ID - ref110 ER - TY - JOUR AU - Shen, J. AU - Frye, M. AU - Lee, B. L. PY - 2014 DA - 2014// TI - Targeting Ve-Ptp activates Tie2 and stabilizes the ocular vasculature JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI74527 DO - 10.1172/JCI74527 ID - Shen2014 ER - TY - JOUR AU - Campochiaro, P. A. AU - Sophie, R. AU - Tolentino, M. PY - 2015 DA - 2015// TI - Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2 JO - Ophthalmology VL - 122 UR - https://doi.org/10.1016/j.ophtha.2014.09.023 DO - 10.1016/j.ophtha.2014.09.023 ID - Campochiaro2015 ER - TY - JOUR AU - Campochiaro, P. A. AU - Khanani, A. AU - Singer, M. PY - 2016 DA - 2016// TI - Enhanced benefit in diabetic macular edema from Akb-9778 Tie2 activation combined with vascular endothelial growth factor suppression JO - Ophthalmology VL - 123 UR - https://doi.org/10.1016/j.ophtha.2016.04.025 DO - 10.1016/j.ophtha.2016.04.025 ID - Campochiaro2016 ER - TY - STD TI - Aerpio Press Release (February 10, 2016). Aerpio therapeutics announces presentation of positive results of Akb-9778 in patients with diabetic retinopathy from time-2 phase 2a study. https://www.businesswire.com/news/home/20160210006109/en/Aerpio-Therapeutics-Announces-Presentation-Positive-Results-AKB-9778. Accessed 4 Apr 2020. UR - https://www.businesswire.com/news/home/20160210006109/en/Aerpio-Therapeutics-Announces-Presentation-Positive-Results-AKB-9778 ID - ref114 ER - TY - STD TI - Aerpio Corporate Presentation. 2019. http://ir.aerpio.com/static-files/7ec12cbe-9bfd-41e4-98fb-569070cd1bf1. Accessed 7 Apr 2020. UR - http://ir.aerpio.com/static-files/7ec12cbe-9bfd-41e4-98fb-569070cd1bf1 ID - ref115 ER - TY - STD TI - Clinicaltrials. Gov. Open label study to assess the efficacy and safety of Akb-9778 in subjects with macular edema due to Rvo. https://clinicaltrials.gov/ct2/show/NCT02387788?term=akb-9778&draw=2&rank=2. Accessed 4 Apr2020. UR - https://clinicaltrials.gov/ct2/show/NCT02387788%3fterm%3dakb-9778%26draw%3d2%26rank%3d2 ID - ref116 ER - TY - STD TI - Aerpio. Arp-1536. https://aerpio.com/pipeline/arp-1536/. Accessed 4 Apr 2020. UR - https://aerpio.com/pipeline/arp-1536/ ID - ref117 ER - TY - STD TI - Brown DM. Phase 1 Study of combination therapy with nesvacumab and aflibercept for neovascular amd and diabetic macular edema. In: American academy of ophthalmology annual meeting. Chicago, IL2016. ID - ref118 ER - TY - STD TI - Clinicaltrials. Gov. Anti-angiopoeitin 2 plus anti-vascular endothelial growth factor as a therapy for neovascular age related macular degeneration: evaluation of a fixed combination intravitreal injection (Onyx). https://clinicaltrials.gov/ct2/show/NCT02713204?term=NCT02713204&draw=2&rank=1.). Accessed 4 Apr 2020. UR - https://clinicaltrials.gov/ct2/show/NCT02713204%3fterm%3dNCT02713204%26draw%3d2%26rank%3d1.) ID - ref119 ER - TY - STD TI - Clinicaltrials. Gov. Anti-vascular endothelial growth factor plus anti-angiopoietin 2 in fixed combination therapy: evaluation for the treatment of diabetic macular edema (Ruby). https://clinicaltrials.gov/ct2/show/NCT02712008?term=nesvacumab&draw=2&rank=3.). Accessed 4 Apr 2020. UR - https://clinicaltrials.gov/ct2/show/NCT02712008%3fterm%3dnesvacumab%26draw%3d2%26rank%3d3.) ID - ref120 ER - TY - STD TI - Regeneron Press Release (November 27, 2017). Regeneron Provides Update on Eylea® (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program. https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-eylear-aflibercept-injection-and. Accessed 4 Apr 2020. UR - https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-eylear-aflibercept-injection-and ID - ref121 ER -